Back to top
more

Curis (CRIS)

(Delayed Data from NSDQ)

$15.22 USD

15.22
19,626

-0.73 (-4.58%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $15.19 -0.03 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CRIS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Curis, Inc. [CRIS]

Reports for Purchase

Showing records 21 - 40 ( 302 total )

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

05/03/2022

Company Report

Pages: 8

Highlights From Non-Deal Roadshow

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

04/11/2022

Daily Note

Pages: 3

FDA Places Partial Clinical Hold on TakeAim Lymphoma Study of Emavusertib

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

04/04/2022

Daily Note

Pages: 3

Partial Clinical Hold Placed on TakeAim Leukemia Study of Emavusertib (CA-4948)

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

02/25/2022

Company Report

Pages: 8

4Q21 Results; Multiple Data Readouts Expected in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

01/07/2022

Company Report

Pages: 8

Positive Updates for Both CA-4948 and CI-8993 Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/10/2021

Company Report

Pages: 6

3Q21 Results; Important Data for CA-4948 in AML and MDS and CI-8993 Safety Data Expected in January

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

11/08/2021

Daily Note

Pages: 3

Combination Therapy Initiated in R/R Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CRIS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

08/04/2021

Company Report

Pages: 8

2Q21 Results; Several Key Milestones Anticipated in 2H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

06/21/2021

Company Report

Pages: 7

Highlights From Virtual Symposium on VISTA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

06/14/2021

Company Report

Pages: 8

More Positive Data From the Phase 1/2 Study of CA-4948 in AML and MDS at EHA 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

05/13/2021

Company Report

Pages: 8

1Q21 Results; EHA Abstract Highlights Impressive Data for CA-4948 in AML and MDS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

04/19/2021

Daily Note

Pages: 3

CA-4948 Receives Orphan Drug Designation for the Treatment of AML and MDS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/17/2021

Company Report

Pages: 8

4Q20 Results; Additional CA-4948 Data in AML and High-Risk MDS Patients Expected Mid-2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

02/09/2021

Daily Note

Pages: 3

First Patient Dosed in Phase 1 Combination Study of CA-4948 With Imbruvica

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

02/02/2021

Daily Note

Pages: 3

Initiation of Phase 2 LUCAS Trial of CA-4948 in MDS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

01/15/2021

Company Report

Pages: 8

Looking to Several Potential Catalysts in 2021; Raise PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

12/08/2020

Company Report

Pages: 7

Positive Data for CA-4948 in AML/MDS; Raising PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

12/08/2020

Company Report

Pages: 8

Positive CA-4948 Data in NHL at ASH; Two Potential Biomarkers Identified

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

11/24/2020

Company Report

Pages: 34

Initiating With Buy Rating and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 75.00

Research Provided by a Third Party